Trial Profile

K-232 phase 3 long-term administration study in patients with primary open-angle glaucoma (POAG), exfoliative glaucoma, pigmentary glaucoma or ocular hypertension (OH)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brimonidine/ripasudil (Primary)
Indications Desquamation; Glaucoma; Ocular hypertension; Pigmentary glaucoma
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Kowa

Most Recent Events

01 Aug 2024 Primary endpoint has been met (Efficacy :Mean IOP reduction from baseline at all measurement points) , according to Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
01 Aug 2024 Results published in the Graefes Archive for Clinical and Experimental Ophthalmology
11 Jan 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com